Intrexon Corporation through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; cell systems informatics; RheoSwitch inducible gene switch; AttSite Recombinases; protein engineering; mAbLogix; and laser-enabled analysis and processing. Intrexon Corporation has collaboration agreements with ZIOPHARM Oncology, Inc.; Synthetic Biologics, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; AquaBounty Technologies, Inc.; S & I Ophthalmic, LLC; Biological & Popular Culture, Inc.; OvaXon, LLC; Intrexon Energy Partners, LLC; and Persea Bio, LLC; and strategic collaboration and licensing agreement with Merck Serono S.A. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.
October 5, 2019
RegMed Investors’ (RMi) closing bell: a “goldilocks” upside move
October 3, 2019
RegMed Investors’ (RMi) closing bell: after weakness, there’s neutrality – like today and it is sure to spiral again
October 3, 2019
RegMed Investors’ (RMi) pre-open: I’m employing oversold recognition software to my portfolio
October 2, 2019
RegMed Investors’ (RMi) closing bell: where the sector meets the road too long traveled
September 26, 2019
RegMed Investors’ (RMi) closing bell: the roller-coaster rolls down
September 18, 2019
RegMed Investors’ (RMi) closing bell: trounced again
September 18, 2019
RegMed Investors’ (RMi) pre-open: expectation
September 17, 2019
Clone of RegMed Investors’ (RMi) closing bell: the sector turns and burns
September 17, 2019
RegMed Investors’ (RMi) closing bell: the sector turns and burns
August 25, 2019
RegMed Investors’ (RMi) Friday’s closing bell: another sector goose egg of a session
35 companies, 1 interpreter!
Insight, foresight and recommendation
Intrexon (NYSE: XON) – Opened 2018 at $13.47, started February at $13.21 and March at $12.90 seeing a high on 3/6 at $15.63. Over last year, the stock declined 45.2%, as against the industry’s gain of 0.1% while developing several candidates in partnership with other companies. Intrexon follows a business model under which it commercializes its technologies through exclusive channel collaborations (ECC), licensing agreements and joint ventures with collaborators that have market and product development expertise as well as sales and marketing capabilities to bring new and improved products and processes to market. Such agreements provide XON with funds in the form of technology access fees along with milestones and other payments. News is always a stimulant to BUY and SELL ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.